Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Cardionovum to launch new Prolimus Biograde stent in Q4 2012

Cardionovum is planning to launch its new Sirolimus-eluting coronary stent system, Prolimus Biograde, in Q4 2012.

The new Prolimus Biograde features thin-stent strut design of just 71 microns which is designed to provide uniform stent coverage, minimize stent-metal-volume and foreign-body effects.

In addition, the Prolimus stent incorporates a diameter-depending 6-8-10 intermediate and closed-cell stent design to ensure a homogenous drug elution into the arterial tissue of the stented lesion segment.

Prolimus Biograde is also coated with Titanium, which functions as a barrier against ‘metal-ion-bleeding that prevents any stent-associated hypersensitivity reaction in diabetic patients, as well as an anti-proliferative drug Rapamycin (Sirolimus) featuring a natural and biodegradable polylactide acid (PLA) polymer.

Cardionovum CEO Michael Orlowski said it is not only the drug on a stent that counts for the optimal patient treatment.

"It also is critically important what remains in the patient´s artery for the patient´s lifetime, after drug elution has gone," Orlowski added.